GLP-1s and AI: managing the cardiometabolic monitoring burden at scale

The GLP-1 receptor agonist boom did not just reshape obesity medicine. It created a monitoring infrastructure problem that most health systems are only beginning to reckon with. Semaglutide and tirzepatide are not set-it-and-forget-it medications. They require dose titration over months, side-effect surveillance, periodic lab review, and ongoing engagement to prevent the discontinuation rates that make the drugs economically counterproductive. At the scale these medications are now being prescribed — tens of millions of active patients in the U.S. alone as of mid-2026 — the monitoring burden is a population health management challenge of the first order.

It is also, increasingly, an AI problem. Or more precisely, an opportunity that AI-enabled care management platforms have moved to fill, with results that are promising enough to be real and variable enough to require scrutiny.

The monitoring burden in practice

Understanding what AI platforms are actually doing here requires understanding what GLP-1 monitoring actually entails. The clinical workload is not complex, but it is high-volume and time-sensitive.

Dose titration typically follows a four-to-twelve week escalation schedule. Patients who tolerate each dose step move to the next; those experiencing significant GI side effects — nausea, vomiting, gastroparesis symptoms — may need to hold, reduce, or switch agents. This determination requires patient-reported symptom data, not just lab values. It requires a clinical decision, but not necessarily a physician decision. Most titration protocols can be executed by a trained nurse or medical assistant following a validated algorithm.

Lab monitoring requirements vary by patient risk profile but typically include HbA1c every three months for the first year, lipid panel at baseline and after six months, renal function monitoring (particularly for patients with baseline CKD), and thyroid monitoring for patients with risk factors. For a panel of five hundred GLP-1 patients, this generates hundreds of lab result reviews per quarter — most of which are normal and require only documentation, a few of which require clinical action.

Side-effect surveillance is the least systematized piece. Patients experiencing significant adverse effects frequently contact the clinic through whatever channel is easiest — MyChart messages, phone calls, pharmacy inquiries — and the responses are inconsistent. A patient who calls about persistent nausea at week six of titration might speak to a nurse who adjusts the dose appropriately, or might be told to call back, or might stop the medication on their own. This last outcome is where the economic and clinical loss is largest.

What AI care management platforms are doing

The platforms that have built specifically for GLP-1 management — and several have, either as standalone products or as modules within broader chronic care platforms — share a recognizable architecture. An automated outreach layer contacts patients at defined intervals via text or app, collecting structured symptom data against a validated questionnaire. A rules-based or ML-driven triage layer stratifies responses by urgency and routes them to appropriate clinical review. A care team dashboard surfaces the patients requiring action, pre-populated with the relevant context: current dose, symptom history, lab values due or overdue, last clinical contact.

The better implementations close the loop. When a patient reports grade-2 nausea at week four, the platform generates a suggested dose-hold recommendation, surfaces it to a reviewing clinician for approval, and sends the patient a personalized message with a revised titration schedule — all within a workflow that takes the clinician three minutes rather than thirty. The patient who would previously have fallen through the cracks gets a response within hours.

The lab tracking piece is more mature, largely because it runs on structured data. Platforms integrated with EHR data can identify patients with overdue HbA1c draws, generate outreach, track lab completion, and flag results outside target range — all without clinical staff touching the workflow until action is required. For large panels, this kind of automated lab surveillance is not a nice-to-have. It is a precondition for managing the population at all.

What health systems and payers need to build or buy

The strategic question for health systems is whether to build GLP-1 management capability within existing infrastructure or to purchase a specialized platform. The honest answer is that most health systems do not have the internal tools to do this well. EHR-native population health modules typically lack the patient engagement layer that drives adherence. The outreach sequencing, the symptom capture instrument, the titration algorithm logic — these require either significant internal development or a vendor relationship.

The relevant evaluation criteria are not primarily clinical. Most of the competing platforms are clinically adequate. The differentiating questions are: How does the platform integrate with the EHR, and in which direction? Can it write back to the chart, or does it create a parallel record? What is the care team capacity model — does the platform reduce FTE requirements, or does it generate new work that requires net new staff? And critically: what are the actual utilization and retention outcomes the vendor can demonstrate in real-world deployments, not controlled pilots?

Payers have a distinct but related problem. They are bearing the drug cost — semaglutide at list price is a significant per-member expense — but often have limited visibility into whether the prescribing health system has the infrastructure to manage adherence and dose optimization. The payers who are moving aggressively are those who have decided they cannot wait for providers to build this capacity and are funding or contracting care management platforms directly, effectively wrapping their own managed programs around the underlying prescribing relationship.

The discontinuation problem is the real test

The clinical and economic case for GLP-1 AI management ultimately rests on one metric: whether it reduces discontinuation rates. The real-world twelve-month discontinuation rate for GLP-1 medications in commercial populations has consistently come in above fifty percent, driven by side effects, cost, access, and inadequate support. Platforms that can demonstrate materially lower discontinuation — through proactive side-effect management, dose optimization, and ongoing engagement — have a compelling value proposition. Those that merely generate more touchpoints without improving retention are adding cost and complexity without clinical payoff.

The data on this is beginning to emerge, and it is heterogeneous. Some deployments show meaningful retention improvements. Others show engagement metrics — message response rates, app usage — without corresponding clinical outcomes. Health systems evaluating these platforms need to demand outcomes data, not activity data, and be skeptical of pilots conducted in unusually motivated patient populations.

The monitoring burden is real. The opportunity for AI-enabled management is real. But the evidence bar for what works needs to rise as fast as the prescribing volume.